|Bid||2.02 x 800|
|Ask||2.03 x 1200|
|Day's Range||2.01 - 2.07|
|52 Week Range||1.29 - 3.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.33|
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Williams ...
CLEVELAND, Aug. 07, 2018-- Athersys, Inc. announced today its financial results for the three months ended June 30, 2018.. Highlights of the second quarter of 2018 and recent events include:. Announced ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Athersys, Inc. (NASDAQ: ATHX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To ...
Athersys, Inc. (ATHX) announced the addition of an experienced manufacturing executive to oversee manufacturing operations and help plan for and lead the Company’s transition into commercial manufacturing of MultiStem®, the Company’s patented and proprietary “off-the-shelf” investigational stem cell therapy. Mr. Gregory Liposky, MBA will serve as the Company’s Senior Vice President of Commercial Manufacturing.
Athersys, Inc. (ATHX) announced today that the first patient has been enrolled its Phase 3 study entitled, MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (“MASTERS-2”) to evaluate MultiStem® cell therapy treatment of patients who have suffered an ischemic stroke. The MASTERS-2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial designed to enroll 300 patients in North America and Europe who have suffered moderate to moderate-severe ischemic stroke.
HENDERSON, NV / ACCESSWIRE / July 12, 2018 / The global regenerative medicine market size is expected to reach USD 5.59 billion by 2025, according to a new report by Grand View Research, Inc. With that being said this market could bring incredible value to shareholders of regenerative medicine companies over the next several years. With BioRestorative Therapies, Inc. (BRTX) we noticed that the market cap of this company is so low it could very well have a lot of room to grow.
CLEVELAND, July 10, 2018-- Athersys, Inc. will release its second quarter 2018 financial results at approximately 4:00 PM Eastern Time on Tuesday, August 7 th, 2018, and will host a conference call shortly ...
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS).
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Five Below Inc (NASDAQ: FIVE ) stock was trading higher ...
Athersys, Inc. (ATHX) announced today that it has entered into an agreement with HEALIOS K.K. (“Healios”) to expand their collaboration into additional therapeutic areas. Under the terms of the agreements, Healios obtained exclusive licenses for the development and commercialization in Japan of MultiStem® therapy for the treatment of acute respiratory distress syndrome (“ARDS”) and of MultiStem cells used in combination with iPSC-derived cells for the treatment of certain organs.
Athersys, Inc. (ATHX) announced today that it has entered into an agreement with HEALIOS K.K. ("Healios") to expand their collaboration into additional therapeutic areas. Under the terms of the agreements, Healios obtained exclusive licenses for the development and commercialization in Japan of MultiStem® therapy for the treatment of acute respiratory distress syndrome ("ARDS") and of MultiStem cells used in combination with iPSC-derived cells for the treatment of certain organs.
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals
Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.
Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Drug pricing has been in the spotlight once again this month when President Donald Trump announced plans to lower prescription drug costs.
BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.
INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.
Assessing Athersys Inc’s (NASDAQ:ATHX) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check to buildRead More...
Levi & Korsinsky announces it has commenced an investigation of Athersys, Inc. concerning possible breaches of Delaware law by the board of directors of the company.